et_companies5 days ago
BULLISH(95%)
hold
India's exports of active pharma ingredients at Rs 41,500 cr surpassed imports in FY25
Read original source+61.1
Market Impact Score
-100 Bearish+100 Bullish
AI Analysis
The Indian pharma sector is focusing on reducing import dependence for APIs, a critical component. Government support through PLI schemes is boosting domestic manufacturing.
Trading Insight
Positive for domestic API manufacturers; identify companies with strong API production capabilities and PLI scheme beneficiaries.
Quick check: SUNPHARMA bullish bias (overbought), CIPLA neutral (+0.8% 1d).
Key Evidence
- •API exports reached Rs 41,500 crore in FY25.
- •API imports were Rs 39,215 crore in FY25.
- •The government's Production Linked Incentive (PLI) scheme aims for self-reliance and reduced import connections, especially with China.
- •Risk flag: Global supply chain disruptions could still impact raw material availability.
- •Risk flag: Intense competition among domestic players.
Sectors:pharma
AI-powered analysis by
Anadi Algo News